Publications

Detailed Information

Changes in treatment outcomes of multidrug-resistant tuberculosis

DC Field Value Language
dc.contributor.authorKwak, N.-
dc.contributor.authorKim, H-R-
dc.contributor.authorYoo, C-G-
dc.contributor.authorKim, Y. W.-
dc.contributor.authorHan, S. K.-
dc.contributor.authorYim, J-J-
dc.date.accessioned2024-08-08T01:40:15Z-
dc.date.available2024-08-08T01:40:15Z-
dc.date.created2018-10-16-
dc.date.created2018-10-16-
dc.date.issued2015-05-
dc.identifier.citationInternational Journal of Tuberculosis and Lung Disease, Vol.19 No.5, pp.525-530-
dc.identifier.issn1027-3719-
dc.identifier.urihttps://hdl.handle.net/10371/207218-
dc.description.abstractSETTING: After several changes in treatment modalities, it is time to re-evaluate treatment outcomes of multidrug-resistant tuberculosis (MDR-TB). OBJECTIVE: To evaluate treatment outcomes, elucidate changes in outcomes over time and identify predictors of treatment success for MDR-TB. DESIGN: Patients diagnosed with MDR-TB at a tertiary referral centre in South Korea between January 2006 and December 2010 were included. Treatment modalities and outcomes were assessed. Predictors of treatment success were analysed using multiple logistic regression. The treatment modalities and outcomes of these patients were compared with those of MDR-TB patients between January 1996 and December 2005. RESULTS: Of the 123 MDR-TB patients diagnosed during the later study period, treatment was successful in 103 (83.7%). Extensive drug resistance (OR 0.31, P = 0.044) and additional resistance to fluoroquinolones (OR 0.23, P = 0.039) were inversely associated with treatment success. The treatment success rate improved from 53.5% in 1996-2000 to 68.8% in 2001-2005 and 83.7% in 2006-2010 (P < 0.001). Improved outcomes were accompanied with more frequent use of later-generation fluoroquinolones and linczolid and less frequent surgical resection. CONCLUSION: Treatment outcomes for MDR-TB improved at a tertiary referral centre in South Korea. The improvement was associated with more frequent use of later-generation fluoroquinolones and linczolid.-
dc.language영어-
dc.publisherInternational Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories-
dc.titleChanges in treatment outcomes of multidrug-resistant tuberculosis-
dc.typeArticle-
dc.identifier.doi10.5588/ijtld.14.0739-
dc.citation.journaltitleInternational Journal of Tuberculosis and Lung Disease-
dc.identifier.wosid000353670200007-
dc.identifier.scopusid2-s2.0-84928883927-
dc.citation.endpage530-
dc.citation.number5-
dc.citation.startpage525-
dc.citation.volume19-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorYoo, C-G-
dc.contributor.affiliatedAuthorKim, Y. W.-
dc.contributor.affiliatedAuthorHan, S. K.-
dc.contributor.affiliatedAuthorYim, J-J-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusINJECTABLE DRUGS-
dc.subject.keywordPlusIMPACT-
dc.subject.keywordPlusLEVOFLOXACIN-
dc.subject.keywordPlusTB-
dc.subject.keywordAuthorfluoroquinolone-
dc.subject.keywordAuthorlinezolid-
dc.subject.keywordAuthorsurgery-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Nontuberculous Mycobacteria, Tuberculosis, multidrug-resistant tuberculosis, 결핵, 다제내성결핵, 비결핵항산균 폐질환

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share